SEER

Seer is a commercial-stage proteomics company whose Proteograph Product Suite has not yet found commercial traction, and the numbers make the stock a balance-sheet story rather than a growth one. Revenue has been essentially flat-to-choppy for four years ($15.5M → $16.7M → $14.2M → $16.6M); the headline FY2025 "+17%" is mostly a rebound off a weak 2024, not durable acceleration. Against that, the company lost $73.6M and burned $44.4M of operating cash, with an operating margin of -470% and a -$466M accumulated deficit. Management itself frames the core risk plainly: it is a 'commercial-stage life sciences technology company with a history of net losses, which we expect to continue,' and concedes 'we may never generate revenue sufficient to offset our expenses' and that the Proteograph market 'may be smaller than estimated.' That is the bear case in the issuer's own words.

What keeps this from being a sell is the balance sheet. Equity is $259M against a $93.7M market cap — the stock trades at roughly 0.36x book and below its net current asset value (current assets $202M less total liabilities $36.8M ≈ $165M, or ~$2.93/share). Liabilities are a trivial 0.14x equity, there is no debt stress, and the loss narrowed 15% YoY while R&D was cut 13%, signaling some cost discipline. Reported cash is $47.3M, but current assets of $202M imply a sizeable marketable-securities buffer beyond that line, giving multiple years of runway against the current ~$44M burn even before any further cost cuts.